[SNB-101] SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
Date2025-01-10
View688
등록된 파일이 없습니다.
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
2025-01-10
SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/
-- SN BioScience today announced that its lead asset SNB-101 has received
Investigational New Drug (IND) clearance from the U.S. Food and Drug
Administration (FDA) for a Phase 1b/2 clinical trial. This achievement
follows the designation of SNB-101 as an orphan drug for small cell lung cancer
in 2023 and its Fast Track designation in 2024. With this latest clearance,
SNB-101 is rapidly advancing toward early commercialization in the U.S. market.
SN BioScience expects to initiate the clinical trials in Q2, 2025.
Validated for ES-SCLC, SNB-101 Eyes 2028
U.S. Market Launch
SN BioScience has revealed details of its
Phase 1b/2 clinical trial for SNB-101, targeting patients diagnosed with
Extensive Stage Small Cell Lung Cancer (ES-SCLC). The trial will concentrate on
dose escalation and optimization to improve both efficacy and safety.
Approximately 55 patients will be enrolled, with a focus on reflecting the
racial diversity of the U.S. population. Furthermore, the study, aimed at
supporting Phase 2 clearance in Europe, will be conducted across South
Korea, the U.S., and Europe. Efficacy, safety, and pharmacokinetics will
serve as the primary endpoints. Following the dose optimization phase, the
company plans to assess SNB-101's efficacy and safety in approximately 100
patients through a single-arm, single-dose, open-label monotherapy study. If
the results are positive, SN BioScience targets early U.S. commercialization,
with market entry expected as early as 2028.
Small cell lung cancer (SCLC), representing
12-15% of all lung cancer cases, is an aggressive disease with a poor
prognosis. Around 70% of patients are diagnosed at an extensive stage, where
the cancer has already spread, resulting in a five-year survival rate of less
than 7%. Despite these challenging statistics, the SCLC treatment market is
expected to grow at a compound annual growth rate (CAGR) of 7-10% from 2023 to
2030, according to Evaluate Pharma, highlighting the urgent need for more
effective therapies. In this context, SNB-101 emerges as a highly promising
treatment option, offering the potential to significantly improve patient
outcomes.
SN BioScience aims to establish its
treatment as a second- or third-line option for patients resistant to existing
therapies. Ultimately, the company seeks to position the therapy as a first- or
second-line standard treatment, potentially in combination with immuno-oncology
agents.
About SN BioScience Inc.
Founded in May 2017, SN BioScience is
a biotech company specializing in drug delivery systems for cancer therapies.
Based in the 2nd Pangyo Techno Valley in Seongnam-si, Gyeonggi-do, Korea, the
company was established by experts in pharmaceutical R&D, world-class bio-polymer
researchers, and clinical professionals. Since its inception, SN BioScience has
focused on the commercialization of innovative technologies, particularly in
the development of nanoliposomes and nanoparticle drug carriers, supported by
advanced pharmacometrics and pharmacokinetics.
SNB-101
SNB-101 is an innovative anticancer drug,
marking the world's first nanoparticle formulation of SN-38, the active
metabolite of irinotecan. Utilizing SN BioScience's dual nano-micelle delivery
system, SNB-101 overcomes the drug resistance and safety issues seen with
traditional treatments. The drug has already been highlighted for its use in
drug-antibody conjugates (ADCs) such as Enhertu® and Trodelvy®. Preclinical
studies suggest that SNB-101 may also be effective against lung, pancreatic,
and stomach cancers, expanding its potential applications in oncology.
※ Please refer to the link below for the related aritcle.
- PREV
- NEXT